Canaccord raised the firm’s price target on Viking Therapeutics (VKTX) to $107 from $106 and keeps a Buy rating on the shares. The firm believes the shares are deeply undervalued given the value attributed to Metsera (MTSR) nd the more advanced nature of Viking’s obesity pipeline. Canaccord views Viking as a highly appealing asset in the obesity space and the leading biotech asset in obesity clinical development.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Viking Therapeutics’ VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating
- Viking Therapeutics’ VK2735 Trials and Strategic Positioning Drive Buy Rating
- Promising Potential of Viking Therapeutics’ VK2735: A Buy Rating Justified by Efficacy in Weight Loss and Metabolic Health